Do analysts prefer TVRD or SPRO?

Tvardi Therapeutics presently has a consensus target price of $18.00, indicating a potential upside of 894.48%. Given Tvardi Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Tvardi Therapeutics is more favorable than Spero Therapeutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Tvardi Therapeutics 1 Sell rating(s) 1 Hold rating(s) 6 Buy rating(s) 1 Strong Buy rating(s) 2.78 Spero Therapeutics 0 Sell rating(s) 2 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00

Does the media refer more to TVRD or SPRO?

In the previous week, Tvardi Therapeutics had 5 more articles in the media than Spero Therapeutics. MarketBeat recorded 7 mentions for Tvardi Therapeutics and 2 mentions for Spero Therapeutics. Spero Therapeutics' average media sentiment score of 0.86 beat Tvardi Therapeutics' score of 0.71 indicating that Spero Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Tvardi Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Spero Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has stronger earnings & valuation, TVRD or TENX?

Tenax Therapeutics is trading at a lower price-to-earnings ratio than Tvardi Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Tvardi Therapeutics N/A N/A -$18.21M -$2.79 N/A Tenax Therapeutics N/A N/A -$52.60M -$1.48 N/A

Is TVRD or TENX more profitable?

Tenax Therapeutics' return on equity of -61.54% beat Tvardi Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Tvardi Therapeutics N/A -145.40% -91.11% Tenax Therapeutics N/A -61.54% -57.42%

Does the media refer more to TVRD or TENX?

In the previous week, Tvardi Therapeutics had 6 more articles in the media than Tenax Therapeutics. MarketBeat recorded 7 mentions for Tvardi Therapeutics and 1 mentions for Tenax Therapeutics. Tvardi Therapeutics' average media sentiment score of 0.71 beat Tenax Therapeutics' score of 0.00 indicating that Tvardi Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Tvardi Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Tenax Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media favor MNOV or TVRD?

In the previous week, Tvardi Therapeutics had 1 more articles in the media than MediciNova. MarketBeat recorded 7 mentions for Tvardi Therapeutics and 6 mentions for MediciNova. Tvardi Therapeutics' average media sentiment score of 0.71 beat MediciNova's score of 0.02 indicating that Tvardi Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment MediciNova 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Tvardi Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to TVRD or HRTX?

In the previous week, Tvardi Therapeutics had 5 more articles in the media than Heron Therapeutics. MarketBeat recorded 7 mentions for Tvardi Therapeutics and 2 mentions for Heron Therapeutics. Heron Therapeutics' average media sentiment score of 0.87 beat Tvardi Therapeutics' score of 0.71 indicating that Heron Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Tvardi Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Heron Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Is TVRD or TLPH more profitable?

Talphera's return on equity of -87.28% beat Tvardi Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Tvardi Therapeutics N/A -145.40% -91.11% Talphera N/A -87.28% -51.36%

Does the media refer more to TVRD or TLPH?

In the previous week, Tvardi Therapeutics had 5 more articles in the media than Talphera. MarketBeat recorded 7 mentions for Tvardi Therapeutics and 2 mentions for Talphera. Tvardi Therapeutics' average media sentiment score of 0.71 beat Talphera's score of 0.28 indicating that Tvardi Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Tvardi Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Talphera 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

Tvardi Therapeutics (TVRD) Competitors

$1.81 -0.05 (-2.69%)

As of 12:33 PM Eastern

Compare

TVRD vs. SPRO, TENX, MNOV, HRTX, and TLPH

Should you buy Tvardi Therapeutics stock or one of its competitors? Tvardi Therapeutics's main competitors and comparable companies include Spero Therapeutics (SPRO), Tenax Therapeutics (TENX), MediciNova (MNOV), Heron Therapeutics (HRTX), and Talphera (TLPH). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does Tvardi Therapeutics compare to Spero Therapeutics?

Tvardi Therapeutics (NASDAQ:TVRD) and Spero Therapeutics (NASDAQ:SPRO) are both small-cap healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their dividends, institutional ownership, risk, valuation, earnings, profitability, media sentiment and analyst recommendations.

In the previous week, Tvardi Therapeutics had 5 more articles in the media than Spero Therapeutics. MarketBeat recorded 7 mentions for Tvardi Therapeutics and 2 mentions for Spero Therapeutics. Spero Therapeutics' average media sentiment score of 0.86 beat Tvardi Therapeutics' score of 0.71 indicating that Spero Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Tvardi Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Spero Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

44.7% of Tvardi Therapeutics shares are owned by institutional investors. Comparatively, 25.6% of Spero Therapeutics shares are owned by institutional investors. 7.4% of Tvardi Therapeutics shares are owned by insiders. Comparatively, 2.9% of Spero Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Spero Therapeutics has higher revenue and earnings than Tvardi Therapeutics. Tvardi Therapeutics is trading at a lower price-to-earnings ratio than Spero Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Tvardi Therapeutics	N/A	N/A	-$18.21M	-$2.79	N/A
Spero Therapeutics	$42.96M	1.68	$8.57M	$0.11	11.27

Tvardi Therapeutics presently has a consensus target price of $18.00, indicating a potential upside of 894.48%. Given Tvardi Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Tvardi Therapeutics is more favorable than Spero Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Tvardi Therapeutics	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.78
Spero Therapeutics	0 Sell rating(s)	2 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00

Tvardi Therapeutics has a beta of 0.39, indicating that its share price is 61% less volatile than the broader market. Comparatively, Spero Therapeutics has a beta of 1.55, indicating that its share price is 55% more volatile than the broader market.

Spero Therapeutics has a net margin of 24.90% compared to Tvardi Therapeutics' net margin of 0.00%. Spero Therapeutics' return on equity of 16.17% beat Tvardi Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Tvardi Therapeutics	N/A	-145.40%	-91.11%
Spero Therapeutics	24.90%	16.17%	12.57%

Summary

Spero Therapeutics beats Tvardi Therapeutics on 9 of the 16 factors compared between the two stocks.

How does Tvardi Therapeutics compare to Tenax Therapeutics?

Tvardi Therapeutics (NASDAQ:TVRD) and Tenax Therapeutics (NASDAQ:TENX) are both small-cap healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their profitability, analyst recommendations, valuation, media sentiment, institutional ownership, risk, earnings and dividends.

Tvardi Therapeutics presently has a consensus target price of $18.00, suggesting a potential upside of 894.48%. Tenax Therapeutics has a consensus target price of $14.00, suggesting a potential upside of 667.12%. Given Tvardi Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Tvardi Therapeutics is more favorable than Tenax Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Tvardi Therapeutics	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.78
Tenax Therapeutics	1 Sell rating(s)	3 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.56

Tvardi Therapeutics has a beta of 0.39, suggesting that its stock price is 61% less volatile than the broader market. Comparatively, Tenax Therapeutics has a beta of 0.93, suggesting that its stock price is 7% less volatile than the broader market.

44.7% of Tvardi Therapeutics shares are held by institutional investors. Comparatively, 1.7% of Tenax Therapeutics shares are held by institutional investors. 7.4% of Tvardi Therapeutics shares are held by insiders. Comparatively, 10.8% of Tenax Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Tenax Therapeutics' return on equity of -61.54% beat Tvardi Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Tvardi Therapeutics	N/A	-145.40%	-91.11%
Tenax Therapeutics	N/A	-61.54%	-57.42%

In the previous week, Tvardi Therapeutics had 6 more articles in the media than Tenax Therapeutics. MarketBeat recorded 7 mentions for Tvardi Therapeutics and 1 mentions for Tenax Therapeutics. Tvardi Therapeutics' average media sentiment score of 0.71 beat Tenax Therapeutics' score of 0.00 indicating that Tvardi Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Tvardi Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Tenax Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Tenax Therapeutics is trading at a lower price-to-earnings ratio than Tvardi Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Tvardi Therapeutics	N/A	N/A	-$18.21M	-$2.79	N/A
Tenax Therapeutics	N/A	N/A	-$52.60M	-$1.48	N/A

Summary

Tvardi Therapeutics beats Tenax Therapeutics on 8 of the 13 factors compared between the two stocks.

How does Tvardi Therapeutics compare to MediciNova?

MediciNova (NASDAQ:MNOV) and Tvardi Therapeutics (NASDAQ:TVRD) are both small-cap healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, risk, institutional ownership, valuation, media sentiment, analyst recommendations, dividends and profitability.

MediciNova has a beta of 0.63, meaning that its stock price is 37% less volatile than the broader market. Comparatively, Tvardi Therapeutics has a beta of 0.39, meaning that its stock price is 61% less volatile than the broader market.

9.9% of MediciNova shares are held by institutional investors. Comparatively, 44.7% of Tvardi Therapeutics shares are held by institutional investors. 14.0% of MediciNova shares are held by company insiders. Comparatively, 7.4% of Tvardi Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

MediciNova has higher revenue and earnings than Tvardi Therapeutics. MediciNova is trading at a lower price-to-earnings ratio than Tvardi Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
MediciNova	$410K	183.67	-$12M	-$0.21	N/A
Tvardi Therapeutics	N/A	N/A	-$18.21M	-$2.79	N/A

In the previous week, Tvardi Therapeutics had 1 more articles in the media than MediciNova. MarketBeat recorded 7 mentions for Tvardi Therapeutics and 6 mentions for MediciNova. Tvardi Therapeutics' average media sentiment score of 0.71 beat MediciNova's score of 0.02 indicating that Tvardi Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
MediciNova	2 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Tvardi Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

MediciNova presently has a consensus target price of $8.33, suggesting a potential upside of 444.66%. Tvardi Therapeutics has a consensus target price of $18.00, suggesting a potential upside of 894.48%. Given Tvardi Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Tvardi Therapeutics is more favorable than MediciNova.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
MediciNova	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.67
Tvardi Therapeutics	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.78

Tvardi Therapeutics has a net margin of 0.00% compared to MediciNova's net margin of -1,168.70%. MediciNova's return on equity of -26.51% beat Tvardi Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
MediciNova	-1,168.70%	-26.51%	-24.39%
Tvardi Therapeutics	N/A	-145.40%	-91.11%

Summary

Tvardi Therapeutics beats MediciNova on 8 of the 15 factors compared between the two stocks.

How does Tvardi Therapeutics compare to Heron Therapeutics?

Tvardi Therapeutics (NASDAQ:TVRD) and Heron Therapeutics (NASDAQ:HRTX) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their risk, media sentiment, valuation, institutional ownership, earnings, dividends, analyst recommendations and profitability.

Tvardi Therapeutics has a beta of 0.39, indicating that its share price is 61% less volatile than the broader market. Comparatively, Heron Therapeutics has a beta of 1.65, indicating that its share price is 65% more volatile than the broader market.

44.7% of Tvardi Therapeutics shares are held by institutional investors. Comparatively, 80.0% of Heron Therapeutics shares are held by institutional investors. 7.4% of Tvardi Therapeutics shares are held by company insiders. Comparatively, 6.1% of Heron Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

In the previous week, Tvardi Therapeutics had 5 more articles in the media than Heron Therapeutics. MarketBeat recorded 7 mentions for Tvardi Therapeutics and 2 mentions for Heron Therapeutics. Heron Therapeutics' average media sentiment score of 0.87 beat Tvardi Therapeutics' score of 0.71 indicating that Heron Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Tvardi Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Heron Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Tvardi Therapeutics has a net margin of 0.00% compared to Heron Therapeutics' net margin of -22.52%. Tvardi Therapeutics' return on equity of -145.40% beat Heron Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Tvardi Therapeutics	N/A	-145.40%	-91.11%
Heron Therapeutics	-22.52%	-293.02%	-10.00%

Tvardi Therapeutics currently has a consensus price target of $18.00, suggesting a potential upside of 894.48%. Heron Therapeutics has a consensus price target of $2.00, suggesting a potential upside of 534.92%. Given Tvardi Therapeutics' stronger consensus rating and higher possible upside, research analysts plainly believe Tvardi Therapeutics is more favorable than Heron Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Tvardi Therapeutics	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.78
Heron Therapeutics	1 Sell rating(s)	3 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Tvardi Therapeutics has higher earnings, but lower revenue than Heron Therapeutics. Heron Therapeutics is trading at a lower price-to-earnings ratio than Tvardi Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Tvardi Therapeutics	N/A	N/A	-$18.21M	-$2.79	N/A
Heron Therapeutics	$154.90M	0.39	-$20.19M	-$0.19	N/A

Summary

Tvardi Therapeutics beats Heron Therapeutics on 10 of the 16 factors compared between the two stocks.

How does Tvardi Therapeutics compare to Talphera?

Tvardi Therapeutics (NASDAQ:TVRD) and Talphera (NASDAQ:TLPH) are both small-cap healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their analyst recommendations, profitability, dividends, earnings, valuation, institutional ownership, media sentiment and risk.

Tvardi Therapeutics has a beta of 0.39, indicating that its stock price is 61% less volatile than the broader market. Comparatively, Talphera has a beta of 0.69, indicating that its stock price is 31% less volatile than the broader market.

44.7% of Tvardi Therapeutics shares are owned by institutional investors. Comparatively, 37.7% of Talphera shares are owned by institutional investors. 7.4% of Tvardi Therapeutics shares are owned by company insiders. Comparatively, 3.5% of Talphera shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

In the previous week, Tvardi Therapeutics had 5 more articles in the media than Talphera. MarketBeat recorded 7 mentions for Tvardi Therapeutics and 2 mentions for Talphera. Tvardi Therapeutics' average media sentiment score of 0.71 beat Talphera's score of 0.28 indicating that Tvardi Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Tvardi Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Talphera	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Talphera's return on equity of -87.28% beat Tvardi Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Tvardi Therapeutics	N/A	-145.40%	-91.11%
Talphera	N/A	-87.28%	-51.36%

Tvardi Therapeutics currently has a consensus price target of $18.00, indicating a potential upside of 894.48%. Talphera has a consensus price target of $3.00, indicating a potential upside of 147.93%. Given Tvardi Therapeutics' stronger consensus rating and higher probable upside, research analysts clearly believe Tvardi Therapeutics is more favorable than Talphera.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Tvardi Therapeutics	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.78
Talphera	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25

Talphera has higher revenue and earnings than Tvardi Therapeutics. Talphera is trading at a lower price-to-earnings ratio than Tvardi Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Tvardi Therapeutics	N/A	N/A	-$18.21M	-$2.79	N/A
Talphera	$30K	2,093.70	-$14.29M	-$0.27	N/A

Summary

Tvardi Therapeutics beats Talphera on 9 of the 15 factors compared between the two stocks.

Get Tvardi Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding TVRD and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

TVRD vs. The Competition

Export

Metric	Tvardi Therapeutics	Pharmaceuticals Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$24.14M	$12.39B	$7.28B	$12.76B
Dividend Yield	N/A	2.62%	2.54%	10.79%
P/E Ratio	-0.65	780.39	271.38	24.12
Price / Sales	N/A	792.29	612.61	78.45
Price / Cash	N/A	15.47	29.03	36.90
Price / Book	0.81	10.44	11.17	6.40
Net Income	-$18.21M	$2.80B	$3.46B	$348.28M
7 Day Performance	-2.69%	2.27%	2.07%	1.29%
1 Month Performance	-27.89%	4.72%	7.44%	5.47%
1 Year Performance	-93.55%	6.93%	24.72%	16.27%

Tvardi Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
TVRD Tvardi Therapeutics	3.8779 of 5 stars	$1.81 -2.7%	$18.00 +894.5%	-93.4%	$24.14M	N/A	N/A	80	Analyst Upgrade
SPRO Spero Therapeutics	2.0101 of 5 stars	$1.23 -0.8%	N/A	-34.8%	$71.22M	$66.80M	11.18	150
TENX Tenax Therapeutics	2.4959 of 5 stars	$1.80 -1.6%	$14.00 +677.8%	-70.8%	$67.36M	N/A	N/A	9	Gap Down
MNOV MediciNova	1.7877 of 5 stars	$1.31 flat	$8.33 +536.1%	+5.9%	$64.48M	$410K	N/A	10
HRTX Heron Therapeutics	2.3468 of 5 stars	$0.34 +0.7%	$2.00 +494.0%	-77.3%	$63.92M	$154.90M	N/A	300

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:TVRD) was last updated on 8/24/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Tvardi Therapeutics (TVRD) Competitors

TVRD vs. SPRO, TENX, MNOV, HRTX, and TLPH

How does Tvardi Therapeutics compare to Spero Therapeutics?

Summary

How does Tvardi Therapeutics compare to Tenax Therapeutics?

Summary

How does Tvardi Therapeutics compare to MediciNova?

Summary

How does Tvardi Therapeutics compare to Heron Therapeutics?

Summary

How does Tvardi Therapeutics compare to Talphera?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

TVRD vs. The Competition

Tvardi Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Tvardi Therapeutics (TVRD) Competitors

TVRD vs. SPRO, TENX, MNOV, HRTX, and TLPH

How does Tvardi Therapeutics compare to Spero Therapeutics?

Does the media refer more to TVRD or SPRO?

Do insiders and institutionals believe in TVRD or SPRO?

Which has stronger earnings and valuation, TVRD or SPRO?

Do analysts prefer TVRD or SPRO?

Which has more risk and volatility, TVRD or SPRO?

Is TVRD or SPRO more profitable?

Summary

How does Tvardi Therapeutics compare to Tenax Therapeutics?

Do analysts recommend TVRD or TENX?

Which has more volatility and risk, TVRD or TENX?

Do institutionals and insiders have more ownership in TVRD or TENX?

Is TVRD or TENX more profitable?

Does the media refer more to TVRD or TENX?

Which has stronger earnings & valuation, TVRD or TENX?

Summary

How does Tvardi Therapeutics compare to MediciNova?

Which has more volatility and risk, MNOV or TVRD?

Do institutionals & insiders believe in MNOV or TVRD?

Which has better valuation & earnings, MNOV or TVRD?

Does the media favor MNOV or TVRD?

Do analysts rate MNOV or TVRD?

Is MNOV or TVRD more profitable?

Summary

How does Tvardi Therapeutics compare to Heron Therapeutics?

Which has more volatility and risk, TVRD or HRTX?

Do insiders & institutionals believe in TVRD or HRTX?

Does the media refer more to TVRD or HRTX?

Is TVRD or HRTX more profitable?

Do analysts rate TVRD or HRTX?

Which has better earnings & valuation, TVRD or HRTX?

Summary

How does Tvardi Therapeutics compare to Talphera?

Which has more risk & volatility, TVRD or TLPH?

Do institutionals and insiders have more ownership in TVRD or TLPH?

Does the media refer more to TVRD or TLPH?

Is TVRD or TLPH more profitable?

Do analysts rate TVRD or TLPH?

Which has better valuation and earnings, TVRD or TLPH?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

TVRD vs. The Competition

Tvardi Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools